HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Cabo/Ifos in Ewing Sarcoma and Osteosarcoma (CaIRS trial)
This study is now recruiting.
This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy. The purpose of this study is to find the best dose of a drug called cabozantinib ("the study drug") to give to patients in combination with a routine chemotherapy drug called ifosfamide.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.
Eligibility & Criteria
IRB #:
22-019876
Official Title:
A phase I trial of Cabozantinib (XL184) in combination with high-dose Ifosfamide in adults and children with relapsed/refractory Ewing sarcoma and osteosarcoma (CaIRS trial)
Study Phase:
Phase I
Eligible Age Range:
5 - 40 Years
Gender:
All
Visit Criteria
As a participant in the research, you will:
- Take cabozantinib (the study drug) by mouth once a day, in combination with routine chemotherapy drug ifosfamide given intravenously on days 1-5 of each cycle
- Complete frequent clinic visits at CHOP Philadelphia campus
- Have frequent blood tests
- Have EKGs and echocardiograms for clinical care purposes
- Have periodic imaging performed as part of your regular cancer care to evaluate your response to treatment
- Have research genetic tests (if not previously done clinically)
- Submit leftover tissue samples to the study repository
- Have fresh tissue samples collected (if you have a routine biopsy)
Leader